MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$85,389K
Net Income
-$29,530K
Net Profit Margin
-34.58%
Unit: Thousand (K) dollars
Revenue Breakdown
Precision Diagnostics
Anatomic Pathology
Biopharma Services
Revenue From Contract With Custo...
Revenue Breakdown
Clinical Insurance Contracts
Clinical Institutional Contracts
Clinical Patient Contracts
Revenue Breakdown
US
Non Us
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
85,389
71,138
83,336
84,069
Cost of revenue
59,710
49,648
50,754
48,557
Gross profit
25,679
21,490
32,582
35,512
Research and development
14,554
14,176
14,170
13,860
Selling and marketing
15,228
12,221
10,978
11,642
General and administrative
27,195
27,684
41,646
23,335
Amortization of intangible assets
2,603
2,031
2,026
2,025
Intangible impairment loss
2,172
-
-
-
Total operating expenses
61,752
56,112
68,820
50,862
Operating loss
-36,073
-34,622
-36,238
-15,350
Interest income
6,404
8,651
6,936
7,874
Interest expense
59
17
16
28
Equity securities impairment gain
0
-
0
-
Other income, net
38
10
44
-5
Total other income (expense), net
6,383
8,644
6,964
7,841
Loss before income taxes
-29,690
-25,978
-29,274
-7,509
Provision for (benefit from) income taxes
29
-704
-5,624
-683
Net loss from consolidated operations
-29,719
-25,274
-23,650
-6,826
Net loss attributable to noncontrolling interest
-189
-448
-232
-218
Net loss attributable to fulgent
-29,530
-24,826
-23,418
-6,608
Basic Average Shares
28,005,000
30,881,000
30,983,000
30,749,000
Diluted Average Shares
28,005,000
30,881,000
30,983,000
30,749,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
3
Net loss
attributable to fulgent
-$29,530K
(-55.77%↓ Y/Y)
Net loss
attributable to...
-$189K
(36.79%↑ Y/Y)
Precision Diagnostics
$41,453K
Anatomic Pathology
$37,497K
Biopharma Services
$6,409K
Revenue From Contract
With Customer...
$30K
Net loss from
consolidated operations
-$29,719K
(-54.34%↓ Y/Y)
Interest income
$6,404K
(-20.85%↓ Y/Y)
Laboratory
Services-Operating Segments
$85,359K
Therapeutic Development
$30K
Other income, net
$38K
(-17.39%↓ Y/Y)
Loss before income
taxes
-$29,690K
(-37.97%↓ Y/Y)
Provision for (benefit
from) income taxes
$29K
(101.28%↑ Y/Y)
Total other income
(expense), net
$6,383K
(453.43%↑ Y/Y)
Revenue
$85,389K
(4.38%↑ Y/Y)
Interest expense
$59K
(247.06%↑ Y/Y)
Operating loss
-$36,073K
(-82.99%↓ Y/Y)
Gross profit
$25,679K
(-25.43%↓ Y/Y)
Cost of revenue
$59,710K
(26.06%↑ Y/Y)
Total operating
expenses
$61,752K
(14.04%↑ Y/Y)
General and
administrative
$27,195K
(3.04%↑ Y/Y)
Selling and marketing
$15,228K
(23.95%↑ Y/Y)
Research and development
$14,554K
(7.97%↑ Y/Y)
Amortization of intangible
assets
$2,603K
(30.80%↑ Y/Y)
Intangible impairment loss
$2,172K
Buy us a coffee
Fulgent Genetics, Inc. (FLGT)
Fulgent Genetics, Inc. (FLGT)